Embecta Corp (EMBC) - Net Assets
Based on the latest financial reports, Embecta Corp (EMBC) has net assets worth $-613.10 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.06 Billion) and total liabilities ($1.68 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Embecta Corp carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-613.10 Million |
| % of Total Assets | -57.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -209.63% |
| 10-Year Change | N/A |
| Growth Volatility | 117.09 |
Embecta Corp - Net Assets Trend (2019–2025)
This chart illustrates how Embecta Corp's net assets have evolved over time, based on quarterly financial data. Also explore how large is Embecta Corp's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Embecta Corp (2019–2025)
The table below shows the annual net assets of Embecta Corp from 2019 to 2025. For live valuation and market cap data, see EMBC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $-651.20 Million | +11.80% |
| 2024-09-30 | $-738.30 Million | +10.15% |
| 2023-09-30 | $-821.70 Million | +7.82% |
| 2022-09-30 | $-891.40 Million | -250.07% |
| 2021-09-30 | $594.00 Million | +3.85% |
| 2020-09-30 | $572.00 Million | -7.59% |
| 2019-09-30 | $619.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Embecta Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44560000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $600.00K | % |
| Other Comprehensive Income | $-285.60 Million | % |
| Other Components | $80.00 Million | % |
| Total Equity | $-650.60 Million | 100.00% |
Embecta Corp Competitors by Market Cap
The table below lists competitors of Embecta Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RIDLEY CORP. LTD
F:RI6
|
$546.64 Million |
|
Hunan Huamin Holdings Co Ltd
SHE:300345
|
$546.79 Million |
|
Northrim BanCorp Inc
NASDAQ:NRIM
|
$546.82 Million |
|
Jiangsu Hengxing New Material
SHG:603276
|
$547.25 Million |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
$546.58 Million |
|
CHC Resources Corp
TW:9930
|
$546.56 Million |
|
Shenyang Brilliant Elevator Group Co Ltd
SHE:002689
|
$546.56 Million |
|
TVS Supply Chain Solutions Limited
NSE:TVSSCS
|
$546.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Embecta Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -738,300,000 to -650,600,000, a change of 87,700,000.
- Net income of 95,400,000 contributed positively to equity growth.
- Dividend payments of 35,000,000 reduced retained earnings.
- Share repurchases of 5,700,000 reduced equity.
- Other comprehensive income increased equity by 7,200,000.
- Other factors increased equity by 25,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $95.40 Million | +14.66% |
| Dividends Paid | $35.00 Million | -5.38% |
| Share Repurchases | $5.70 Million | -0.88% |
| Other Comprehensive Income | $7.20 Million | +1.11% |
| Other Changes | $25.80 Million | +3.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Embecta Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $10.12 | $9.23 | x |
| 2020-09-30 | $10.04 | $9.23 | x |
| 2021-09-30 | $10.46 | $9.23 | x |
| 2022-09-30 | $-15.62 | $9.23 | x |
| 2023-09-30 | $-14.23 | $9.23 | x |
| 2024-09-30 | $-12.66 | $9.23 | x |
| 2025-09-30 | $-11.04 | $9.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Embecta Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.83%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (31.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 74.87% | 38.95% | 1.49x | 1.29x | $374.30 Million |
| 2020 | 74.76% | 39.39% | 1.47x | 1.29x | $370.40 Million |
| 2021 | 69.83% | 35.61% | 1.48x | 1.33x | $355.40 Million |
| 2022 | 0.00% | 19.80% | 1.04x | 0.00x | $312.74 Million |
| 2023 | 0.00% | 6.28% | 0.92x | 0.00x | $152.57 Million |
| 2024 | 0.00% | 6.97% | 0.87x | 0.00x | $152.13 Million |
| 2025 | 0.00% | 8.83% | 0.99x | 0.00x | $160.46 Million |
Industry Comparison
This section compares Embecta Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $870,414,600
- Average return on equity (ROE) among peers: -28.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Embecta Corp (EMBC) | $-613.10 Million | 74.87% | N/A | $546.60 Million |
| Akoya Biosciences Inc (AKYA) | $18.57 Million | -89.96% | 3.18x | $64.44 Million |
| Align Technology Inc (ALGN) | $99.40 Million | -98.06% | 0.19x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $424.49 Million | -6.25% | 0.30x | $444.32 Million |
| AptarGroup Inc (ATR) | $1.28 Billion | 13.56% | 0.59x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.44 Billion |
| Avinger Inc (AVGR) | $-143.87 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $62.68 Million | -121.71% | 0.29x | $156.14 Million |
| Avantor Inc (AVTR) | $-3.05 Billion | 0.00% | 0.00x | $5.43 Billion |
| Azenta Inc (AZTA) | $415.04 Million | 3.07% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $9.12 Billion | 6.60% | 0.88x | $8.85 Billion |
About Embecta Corp
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors… Read more